Given the importance of GCGR and GLP1R as therapeutic targets in type II diabetes [21,22] and obesity [23,24], as well as GLP1R’s implication in neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyloid lateral sclerosis (ALS) [21,25,26], we established split TEV assays for those receptors as well. The gene discussed is GCGR; the disease is amyotrophic lateral sclerosis.